| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 17376351
[patent_doc_number] => RE048908
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2022-02-01
[patent_title] => DNA vector production system
[patent_app_type] => reissue
[patent_app_number] => 16/668950
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 9
[patent_no_of_words] => 13144
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668950
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/668950 | DNA vector production system | Oct 29, 2019 | Issued |
| 16/536121 | Anti-Leukocyte Recruitment Therapy for the Treatment of Seizures and Epilepsy | Aug 7, 2019 | Abandoned |
| 16/458942 | INTRANASAL VACCINATION DOSAGE REGIMEN | Jun 30, 2019 | Abandoned |
| 16/442939 | Method for Purifying RNA on a Preparative Scale by Means of HPLC | Jun 16, 2019 | Abandoned |
| 16/441931 | CANINE INFLUENZA VIRUS AND VACCINE THEREFORE | Jun 13, 2019 | Abandoned |
| 16/442284 | ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3 | Jun 13, 2019 | Abandoned |
| 16/442278 | ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3 | Jun 13, 2019 | Abandoned |
| 16/434295 | A Cartridge Used in a Smoking Device for Vaporization | Jun 6, 2019 | Abandoned |
| 16/418336 | METHOD AND PRODUCT FOR TREATING MOUTH-RELATED DISORDERS | May 20, 2019 | Abandoned |
Array
(
[id] => 17376352
[patent_doc_number] => RE048909
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2022-02-01
[patent_title] => Tagged oligonucleotides and their use in nucleic acid amplification methods
[patent_app_type] => reissue
[patent_app_number] => 16/398161
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 22
[patent_no_of_words] => 37886
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 329
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398161
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/398161 | Tagged oligonucleotides and their use in nucleic acid amplification methods | Apr 28, 2019 | Issued |
Array
(
[id] => 17305667
[patent_doc_number] => RE048863
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-12-28
[patent_title] => Compositions relating to a mutant
[patent_app_type] => reissue
[patent_app_number] => 16/388011
[patent_app_country] => US
[patent_app_date] => 2019-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 56
[patent_no_of_words] => 62110
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388011
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/388011 | Compositions relating to a mutant | Apr 17, 2019 | Issued |
Array
(
[id] => 17305666
[patent_doc_number] => RE048862
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-12-28
[patent_title] => Compositions relating to a mutant
[patent_app_type] => reissue
[patent_app_number] => 16/387999
[patent_app_country] => US
[patent_app_date] => 2019-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 56
[patent_no_of_words] => 61694
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387999
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/387999 | Compositions relating to a mutant | Apr 17, 2019 | Issued |
Array
(
[id] => 17087948
[patent_doc_number] => RE048731
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-09-14
[patent_title] => Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
[patent_app_type] => reissue
[patent_app_number] => 16/387315
[patent_app_country] => US
[patent_app_date] => 2019-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49778
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387315
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/387315 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | Apr 16, 2019 | Issued |
Array
(
[id] => 16968694
[patent_doc_number] => RE048651
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-07-20
[patent_title] => Production cell line enhancers
[patent_app_type] => reissue
[patent_app_number] => 16/387134
[patent_app_country] => US
[patent_app_date] => 2019-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 11034
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387134
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/387134 | Production cell line enhancers | Apr 16, 2019 | Issued |
Array
(
[id] => 17176762
[patent_doc_number] => RE048787
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-10-26
[patent_title] => Humanised antibodies
[patent_app_type] => reissue
[patent_app_number] => 16/378731
[patent_app_country] => US
[patent_app_date] => 2019-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 19
[patent_no_of_words] => 15619
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16378731
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/378731 | Humanised antibodies | Apr 8, 2019 | Issued |
Array
(
[id] => 16907541
[patent_doc_number] => RE048599
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-06-22
[patent_title] => Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
[patent_app_type] => reissue
[patent_app_number] => 16/366676
[patent_app_country] => US
[patent_app_date] => 2019-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 36
[patent_no_of_words] => 30682
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366676
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/366676 | Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use | Mar 26, 2019 | Issued |
Array
(
[id] => 16784362
[patent_doc_number] => RE048536
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2021-04-27
[patent_title] => Collagen sponge
[patent_app_type] => reissue
[patent_app_number] => 16/364805
[patent_app_country] => US
[patent_app_date] => 2019-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 7122
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364805
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/364805 | Collagen sponge | Mar 25, 2019 | Issued |
| 16/362585 | MODULATION OF CD40 EXPRESSION | Mar 21, 2019 | Abandoned |
Array
(
[id] => 17328707
[patent_doc_number] => RE048890
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2022-01-11
[patent_title] => Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
[patent_app_type] => reissue
[patent_app_number] => 16/283631
[patent_app_country] => US
[patent_app_date] => 2019-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 17896
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16283631
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/283631 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation | Feb 21, 2019 | Issued |
| 96/000268 | STABLE CRYSTAL FORM OF TIPIRACIL HYDROCHLORIDE AND CRYSTALLIZATION METHOD FOR THE SAME | Aug 1, 2018 | Pending |